Prophylaxis Durations and Risks of Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients: An International, Multicenter Cohort Study

Anja Lindis Dahl, Oriol Manuel, Michael Koller, Joanne Reekie, Erich Tusch, Kasper Moestrup, Michael Perch, Kasper Rossing, Nicolai Schultz, Soren Schwartz Sorensen, Kristian Schønning, Jens Lundgren, Nicolas Johannes Mueller, Marie Helleberg
Transplant Infectious Disease · Wiley · 2026-10-09 · DOI: 10.1111/tid.70321

Аннотация

ABSTRACT Background The optimal duration of cytomegalovirus (CMV) prophylaxis in solid organ transplant recipients (SOTr) remains undetermined. We evaluated real‐life preventive strategies on the incidence of CMV disease in an international SOTr cohort. Methods All CMV IgG donor (D)+/recipient (R)− or R+ SOTr in Zürich, Lausanne, and Copenhagen (2008–2022) were followed 12‐month post‐transplantation. Multivariable Poisson regression examined associations between antiviral prophylaxis duration and risk of CMV infection and CMV disease at time of infection diagnosis. Results We included 3203 non‐lung (2057 kidney, 815 liver, 331 heart) and 620 lung transplant recipients. Strategies for CMV prophylaxis durations varied from none to ≥ 12 months. For D+/R− non‐lung SOTr, no prophylaxis with preemptive therapy only versus 3 months of prophylaxis was associated with higher risk of CMV infection and disease (adjusted incidence rate ratio [aIRR] [95% CI] 2.46 [1.69–3.57], and 2.82 [1.18–6.68]). Risk did not differ between 3 and 6 months of prophylaxis. For D+/R− lung transplant recipients, 3 versus 6 months of prophylaxis was associated with higher risk of CMV infection and high CMV DNAemia (2.74 [1.36–5.52] and 8.10 [1.89–41.90]), but not significantly higher risk of CMV disease. Irrespective of antiviral prophylaxis duration, incidence of CMV disease was lower among R+ compared to D+/R− SOTr. Conclusions In a setting with CMV surveillance after prophylaxis, 3 months of antiviral prophylaxis seems adequate to prevent CMV disease in D+/R− non‐lung SOTr, whereas lung transplant recipients may benefit from longer duration of prophylaxis. Risk of CMV disease was low among R+ SOTr, irrespective of antiviral prophylaxis.

Читать у издателя →

Похожие статьи